Effects of ACE inhibitors and angiotensin receptor blockers: protocol for a UK cohort study using routinely collected electronic health records with validation against the ONTARGET trial.
Paris J BaptisteAngel Y S WongAnna SchultzeMarianne CunningtonJohannes F E MannCatherine ClaseClémence LeyratLaurie A TomlinsonKevin WingPublished in: BMJ open (2022)
Ethical approval has been granted by the London School of Hygiene & Tropical Medicine Ethics Committee (Ref: 22658). The study has been approved by the Independent Scientific Advisory Committee of the UK Medicines and Healthcare Products Regulatory Agency (protocol no. 20_012). Access to the individual patient data from the ONTARGET trial was obtained by the trial investigators. Findings will be submitted to peer-reviewed journals and presented at conferences.
Keyphrases
- electronic health record
- study protocol
- phase iii
- angiotensin converting enzyme
- healthcare
- randomized controlled trial
- phase ii
- clinical trial
- angiotensin ii
- drug administration
- public health
- big data
- transcription factor
- clinical decision support
- mental health
- systematic review
- climate change
- adverse drug
- machine learning
- double blind
- social media
- placebo controlled
- health information